Cervical Cancer

Cervical cancer is the second most common and the fifth most deadly cancer in women. Approximately 80% of cervical cancers occur in developing countries which makes emerging economies such as China a major target market for pharmaceutical companies in the cervical cancer sector. The following expert reports enable buyers to examine the essential issues: supply and demand, forecasts, drug development and discovery, licensing, SWOT analyses, key industry players and more. This is the place for the inside track on market entry opportunities, growth strategies, buyer solutions and potential industry alliances in the area of cervical cancer drug development. Show Less ... more

• 09 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 153.00USD$ 199.00GBP£ 129.00AUD$ 195.00JPY¥ 19,648.00SEK 1 307,00CHF 188.00CAD$ 203.00 Life Science Intelligence, Sep 2012
  This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in September 2012 All companies include technology, market(s), key...

• Chinese Markets for Cervical Cancer Treatment Drugs

  EURO€ 4,280.00USD$ 4,000.00GBP£ 2,432.00AUD$ 5,823.00JPY¥ 490,826.00SEK 34 516,00CHF 5'745.00CAD$ 5,347.00 AMID Co, Sep 2012 , Pages: 189
  China's demand for cervical cancer treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

• 06 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jun 2012 , Pages: 40
  This report includes details on 39 emerging medical technology companies that have been identified by LSI's in-house research team in June 2012 All companies include technology, market(s), key executive,...

• 05 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, May 2012 , Pages: 45
  This report includes details on 41 emerging medical technology companies that have been identified by LSI's in-house research team in May 2012 All companies include technology, market(s), key executive,...

• 04- 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Apr 2012 , Pages: 38
  This report includes details on 37 emerging medical technology companies that have been identified by LSI's in-house research team in April 2012 All companies include technology, market(s), key executive,...

• 03 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Mar 2012 , Pages: 81
  This report includes details on 61 emerging medical technology companies that have been identified by LSI's in-house research team in March 2012 All companies include technology, market(s), key executive,...

• Disease and Therapy Review: Cervical Cancer

  EURO€ 1,065.00USD$ 995.00GBP£ 605.00AUD$ 1,449.00JPY¥ 122,093.00SEK 8 586,00CHF 1'429.00CAD$ 1,330.00 Timely Data Resources, Inc, Feb 2012 , Pages: 14
  Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format These reports are prepared by the senior market...

• 02 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Feb 2012 , Pages: 95
  This report includes details on 43 emerging medical technology companies that have been identified by LSI's in-house research team in February 2012 All companies include technology, market(s), key executive,...

• Global Cervical Cancer Drug Pipeline Capsule - 2012

  EURO€ 323.00USD$ 420.00GBP£ 272.00AUD$ 411.00JPY¥ 41,468.00SEK 2 758,00CHF 396.00CAD$ 428.00 Fore Pharma, Jan 2012 , Pages: 13
  Fore Pharma’s latest report ‘Global Cervical Cancer Drug Pipeline Capsule – 2012’ is an outline of all the key research and development (R&D) activities of the global cervical cancer drug market. It...

• 01 - 2012 Emerging Medical Technologies Spotlight: A Report of Investment & Partnering Opportunities

  EURO€ 304.00USD$ 395.00GBP£ 255.00AUD$ 386.00JPY¥ 39,000.00SEK 2 594,00CHF 372.00CAD$ 402.00 Life Science Intelligence, Jan 2012 , Pages: 101
  This report includes details on 47 emerging medical technology companies that have been identified by LSI's in-house research team in January 2012 All companies include technology, market(s), key executive,...

• Cervical Cancer Global Clinical Trials Review, H2, 2011

  EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00 GlobalData, Aug 2011 , Pages: 121
  Cervical Cancer Global Clinical Trials Review, H2, 2011 Summary GlobalData's clinical trial report, “Cervical Cancer Global Clinical Trials Review, H2, 2011" provides data on the Cervical Cancer clinical...

• Global Cervical Cancer Drug Pipeline Capsule - 2011

  EURO€ 284.00USD$ 370.00GBP£ 239.00AUD$ 362.00JPY¥ 36,531.00SEK 2 429,00CHF 349.00CAD$ 377.00 Fore Pharma, Aug 2011 , Pages: 13
  Fore Pharma’s latest report ‘Global Cervical Cancer Drug Pipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global cervical cancer drug market. It...

• 2011 Global Markets for External Radiation Therapy

  EURO€ 4,996.00USD$ 6,500.00GBP£ 4,203.00AUD$ 6,357.00JPY¥ 641,764.00SEK 42 678,00CHF 6'126.00CAD$ 6,623.00 Life Science Intelligence, May 2011 , Pages: 129
  2011 Global Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 O.U.S. Markets For External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 84
  2011 O U S Markets For External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data...

• 2011 U.S. Markets for External Radiation Therapy

  EURO€ 2,998.00USD$ 3,900.00GBP£ 2,522.00AUD$ 3,814.00JPY¥ 385,059.00SEK 25 607,00CHF 3'676.00CAD$ 3,974.00 Life Science Intelligence, May 2011 , Pages: 66
  2011 U S Markets for External Radiation Therapy is a comprehensive market intelligence solution designed for senior executives who are looking for: - High quality, granular, deeply segmented data -...

• Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010
  The "Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers" report is due to be published in December 2010 This report will cover the following key topics: - Pipeline Overview and Dynamics...